MOH — authorised 4 April 1997
- Marketing authorisation holder: VIIV HLTHCARE
- Status: likely_approved
🇮🇱 Rescriptor in Israel
MOH authorised Rescriptor on 4 April 1997
Marketing authorisation
Rescriptor in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in Israel
Frequently asked questions
Is Rescriptor approved in Israel?
Yes. MOH authorised it on 4 April 1997.
Who is the marketing authorisation holder for Rescriptor in Israel?
VIIV HLTHCARE holds the Israeli marketing authorisation.